- Home
- / Corbus Pharmaceuticals
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Corbus Pharmaceuticals financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$16.2
2024-10-29
Market Capitalization
$195.1 M
2024-10-29
Revenue
$881.7 K
FY, 2021
CreditSafe Score
?
Score changed on Jun 07, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 648.4K | 1.9M | 2.4M | 4.8M | 36.1M | 3.9M | 881.7K | |||||
| General and administrative expense | 1.4M | 3.6M | 6.5M | 9.0M | 13.0M | 23.6M | 28.5M | 20.4M | 18.7M | 13.9M | 16.5M | 15.2M |
| Operating expense total | 2.6M | 9.5M | 21.9M | 35.0M | 61.6M | 113.2M | 126.7M | 34.8M | 48.7M | 85.3M | ||
| EBIT | (2.6M) | (8.9M) | (20.0M) | (32.6M) | (56.7M) | (77.1M) | (122.8M) | (56.0M) | (39.8M) | (45.1M) | (48.7M) | (85.3M) |
| EBIT margin, % | -1365.5% | -1045.6% | -1334.4% | -1176.8% | -213.3% | -3119.2% | ||||||
| Interest income | 2.1K | 3.4K | 1.2M | |||||||||
| Interest expense | 106.7K | 3.0K | 477.0 | 183.1K | 982.8K | 1.0M | (1.8M) | 2.1M | 3.8M | 1.8M | ||
| Net Income | (2.5M) | (8.9M) | (20.0M) | (32.4M) | (55.7M) | (71.5M) | (111.3M) | (45.6M) | (42.3M) | (44.6M) | (40.2M) | (78.5M) |
| EPS | (10.1) | (10.0) | (3.7) | (5.9) |